Tyra Biosciences (TYRA) Institutional Ownership
13F filers reported holding 41.2% of Tyra Biosciences (TYRA) shares as of Sep 30, 2026, across 101 filers.
- Held by 13F filers
- 41.2%
- Sep 30, 2026
- 13F filers
- 101
- quarter ended Sep 30, 2026
- 13F value
- $622.1M
- 28.5M shares
- Quarter's fund flow
- Mild accumulation
- 14 new · 15 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Harris Todd | President and CEO | Acquired · Grant / award | 864 | $9.13 | ↗ |
| Sep 15, 2026 | Rueb Yuliya | Vice President, Finance (PAO) | Acquired · Grant / award | 2,925 | $9.13 | ↗ |
| Sep 15, 2026 | Fuhrman Alan | Chief Financial Officer | Acquired · Grant / award | 951 | $9.13 | ↗ |
| Sep 9, 2026 | Verjee Rehan | director | Acquired · Open-market buy | 972 | $20.58 | ↗ |
| May 28, 2026 | RA CAPITAL MANAGEMENT, LLC | director | Acquired · Grant / award | 13,160Stock Option (Right to Buy) | — | ↗ |
| May 28, 2026 | Verjee Rehan | director | Acquired · Grant / award | 13,160Stock Option (Right to Buy) | — | ↗ |
| May 28, 2026 | Moran Susan | director | Acquired · Grant / award | 13,160Stock Option (Right to Buy) | — | ↗ |
| May 28, 2026 | Simson Jake | director | Acquired · Grant / award | 13,160Stock Option (Right to Buy) | — | ↗ |
| May 28, 2026 | Gulfo Adele M. | director | Acquired · Grant / award | 13,160Stock Option (Right to Buy) | — | ↗ |
| May 28, 2026 | MORE ROBERT J | director | Acquired · Grant / award | 13,160Stock Option (Right to Buy) | — | ↗ |
| May 28, 2026 | Rothenberg Stephen Michael | director | Acquired · Grant / award | 13,160Stock Option (Right to Buy) | — | ↗ |
| May 5, 2026 | Warner Douglas J | Chief Medical Officer | Acquired · Grant / award | 25,000 | — | ↗ |
| May 5, 2026 | Warner Douglas J | Chief Medical Officer | Acquired · Grant / award | 85,000Stock Option (Right to Buy) | — | ↗ |
| May 5, 2026 | Fuhrman Alan | Chief Financial Officer | Acquired · Grant / award | 20,000 | — | ↗ |
| May 5, 2026 | Fuhrman Alan | Chief Financial Officer | Acquired · Grant / award | 67,000Stock Option (Right to Buy) | — | ↗ |
| May 5, 2026 | Harris Todd | President and CEO | Acquired · Grant / award | 79,000 | — | ↗ |
| May 5, 2026 | Harris Todd | President and CEO | Acquired · Grant / award | 265,000Stock Option (Right to Buy) | — | ↗ |
| May 5, 2026 | Ashar Bhavesh | Chief Operating Officer | Acquired · Grant / award | 15,013 | — | ↗ |
| May 5, 2026 | Ashar Bhavesh | Chief Operating Officer | Acquired · Grant / award | 50,295Stock Option (Right to Buy) | — | ↗ |
| May 5, 2026 | Rueb Yuliya | Vice President, Finance (PAO) | Acquired · Grant / award | 8,333 | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Tyra Biosciences do institutions hold?
13F filers reported holding 41.2% of Tyra Biosciences' shares as of Sep 30, 2026, across 101 filers.
How many 13F filers hold Tyra Biosciences?
Tyra Biosciences was held by 101 13F filers as of Sep 30, 2026.
Not investment advice.

